NASDAQ:LRMR Larimar Therapeutics (LRMR) Stock Price, News & Analysis → Trump’s arrest is phase one (From Porter & Company) (Ad) Free LRMR Stock Alerts $8.00 +0.90 (+12.68%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$7.35▼$8.2750-Day Range$6.33▼$8.2452-Week Range$2.18▼$13.68Volume1.01 million shsAverage Volume497,191 shsMarket Capitalization$510.40 millionP/E RatioN/ADividend YieldN/APrice Target$21.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Larimar Therapeutics alerts: Email Address Larimar Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside166.7% Upside$21.33 Price TargetShort InterestBearish6.13% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.82Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.29) to ($2.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.41 out of 5 starsMedical Sector755th out of 928 stocksPharmaceutical Preparations Industry358th out of 437 stocks 3.5 Analyst's Opinion Consensus RatingLarimar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLarimar Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Larimar Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.13% of the outstanding shares of Larimar Therapeutics have been sold short.Short Interest Ratio / Days to CoverLarimar Therapeutics has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Larimar Therapeutics has recently increased by 0.26%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldLarimar Therapeutics does not currently pay a dividend.Dividend GrowthLarimar Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LRMR. Previous Next 3.2 News and Social Media Coverage News SentimentLarimar Therapeutics has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Larimar Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for LRMR on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows2 people have added Larimar Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Larimar Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Larimar Therapeutics is held by insiders.Percentage Held by Institutions91.92% of the stock of Larimar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Larimar Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Larimar Therapeutics are expected to decrease in the coming year, from ($1.29) to ($2.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Larimar Therapeutics is -8.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Larimar Therapeutics is -8.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLarimar Therapeutics has a P/B Ratio of 2.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Larimar Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyTrump’s arrest is phase oneIn this new documentary, you’ll discover the truth about Trump’s criminal conviction, who’s really pulling the puppet strings, and why this is just phase one in their dark plan to reshape America. It’s not just about blocking Trump’s re-election… To get all the details, go here now. About Larimar Therapeutics Stock (NASDAQ:LRMR)Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Read More LRMR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LRMR Stock News HeadlinesJune 1 at 7:32 AM | americanbankingnews.comLarimar Therapeutics' (LRMR) Market Outperform Rating Reaffirmed at JMP SecuritiesMay 31 at 4:11 PM | seekingalpha.comLarimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely RemovedMay 30 at 4:05 PM | globenewswire.comLarimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's AtaxiaMay 29 at 8:45 AM | fool.com2 Potentially High-Reward Growth Stocks to Buy Right NowMay 24, 2024 | americanbankingnews.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by AnalystsMay 23, 2024 | americanbankingnews.comCitigroup Boosts Larimar Therapeutics (NASDAQ:LRMR) Price Target to $14.00May 22, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Larimar Therapeutics Post FDA Clinical Hold Lift and Positive Drug Trial TrajectoryMay 21, 2024 | markets.businessinsider.comBuy Rating Affirmed for Larimar Therapeutics as FDA Lifts Hold on Promising Drug NomlabofuspMay 21, 2024 | msn.comLarimar Therapeutics Advances Friedreich's Ataxia Treatment After FDA Lifts HoldMay 21, 2024 | msn.comLarimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed DrugMay 21, 2024 | markets.businessinsider.comLarimar Therapeutics Says FDA Lifted Partial Clinical Hold For Nomlabofusp In Friedreich's AtaxiaMay 20, 2024 | markets.businessinsider.comOptimistic Outlook for Larimar Therapeutics’ Nomlabofusp Following FDA’s Lifted Partial HoldMay 20, 2024 | finance.yahoo.comLarimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s AtaxiaMay 20, 2024 | globenewswire.comLarimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's AtaxiaMay 14, 2024 | markets.businessinsider.comOptimistic Buy Rating for Larimar Therapeutics Backed by Positive Phase 2 Results and Strategic FDA DiscussionsMay 10, 2024 | finance.yahoo.comCompanies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In GrowthMay 10, 2024 | markets.businessinsider.comBuy Rating for Larimar Therapeutics Backed by Strong Clinical and Financial OutlookMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Larimar Therapeutics Amid Promising Phase II Data and Strategic OLE Study for FA TreatmentMay 9, 2024 | msn.comLarimar Therapeutics files for $300M mixed shelf offeringMay 9, 2024 | investorplace.comLRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q1 2024May 9, 2024 | washingtonpost.comLarimar: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comLarimar Therapeutics Reports First Quarter 2024 Operating and Financial ResultsMarch 18, 2024 | msn.com5 Stocks that Analysts Love in March 2024March 16, 2024 | finance.yahoo.comLRMR Apr 2024 10.000 callMarch 16, 2024 | markets.businessinsider.comBuy Rating Justified: Larimar Therapeutics’ Advancements Towards FDA Approval for FA Drug NomlabofuspSee More Headlines Receive LRMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Larimar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/01/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LRMR CUSIPN/A CIK1374690 Weblarimartx.com Phone(844) 511-9056FaxN/AEmployees42Year FoundedN/APrice Target and Rating Average Stock Price Target$21.33 High Stock Price Target$25.00 Low Stock Price Target$14.00 Potential Upside/Downside+166.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,950,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.69% Return on Assets-32.21% Debt Debt-to-Equity RatioN/A Current Ratio17.99 Quick Ratio17.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.62 per share Price / Book2.21Miscellaneous Outstanding Shares63,800,000Free Float61,059,000Market Cap$510.40 million OptionableOptionable Beta0.96 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Carole S. Ben-Maimon M.D. (Age 65)CEO, President & Director Comp: $865kMr. Michael Celano CPA (Age 65)Secretary & CFO Comp: $577.58kDr. Gopi Shankar M.B.A. (Age 53)Ph.D., Chief Development Officer Comp: $593.02kMr. John BermanVice President of Finance & AdministrationMs. Jennifer Spokes JohanssonVice President of Legal & ComplianceDr. Russell G. Clayton Sr. (Age 63)D.O, D.O., Chief Medical Officer Mr. Francis Michael Conway CPAVP & ControllerMore ExecutivesKey CompetitorsAltimmuneNASDAQ:ALTFulcrum TherapeuticsNASDAQ:FULCArbutus BiopharmaNASDAQ:ABUSKamadaNASDAQ:KMDAParatek PharmaceuticalsNASDAQ:PRTKView All CompetitorsInsiders & InstitutionsOpaleye Management Inc.Sold 449,087 shares on 5/29/2024Ownership: 0.273%Virtu Financial LLCBought 17,578 shares on 5/20/2024Ownership: 0.028%RA Capital Management L.P.Bought 6,045,351 shares on 5/17/2024Ownership: 9.475%Ikarian Capital LLCSold 164,340 shares on 5/17/2024Ownership: 0.687%Janus Henderson Group PLCBought 1,379,900 shares on 5/16/2024Ownership: 6.302%View All Insider TransactionsView All Institutional Transactions LRMR Stock Analysis - Frequently Asked Questions Should I buy or sell Larimar Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Larimar Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LRMR shares. View LRMR analyst ratings or view top-rated stocks. What is Larimar Therapeutics' stock price target for 2024? 6 analysts have issued 1 year target prices for Larimar Therapeutics' stock. Their LRMR share price targets range from $14.00 to $25.00. On average, they expect the company's stock price to reach $21.33 in the next twelve months. This suggests a possible upside of 166.7% from the stock's current price. View analysts price targets for LRMR or view top-rated stocks among Wall Street analysts. How have LRMR shares performed in 2024? Larimar Therapeutics' stock was trading at $4.55 at the beginning of 2024. Since then, LRMR shares have increased by 75.8% and is now trading at $8.00. View the best growth stocks for 2024 here. When is Larimar Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our LRMR earnings forecast. How were Larimar Therapeutics' earnings last quarter? Larimar Therapeutics, Inc. (NASDAQ:LRMR) issued its quarterly earnings results on Thursday, May, 9th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.03. What ETF holds Larimar Therapeutics' stock? iShares Neuroscience and Healthcare ETF holds 1,867 shares of LRMR stock, representing 0.40% of its portfolio. Who are Larimar Therapeutics' major shareholders? Larimar Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (9.48%), Janus Henderson Group PLC (6.30%), Vanguard Group Inc. (3.71%), StemPoint Capital LP (1.16%), Assenagon Asset Management S.A. (1.00%) and Ikarian Capital LLC (0.69%). Insiders that own company stock include Frank E Thomas, James E Flynn, Joseph Truitt, Michael Celano and Thomas Edward Hamilton. View institutional ownership trends. How do I buy shares of Larimar Therapeutics? Shares of LRMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LRMR) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
